TeraFlu® LAR (TeraFlu® LAR)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsplozenges
Composition:

Active substances: benzoxonium chloride 1 mg, lidocaine hydrochloride 1 mg;

Excipients: sorbitol 1000 mg, microcrystalline cellulose 20 mg, macrogol 6000 25 mg, corn starch 55 mg, sodium saccharinate 4 mg, sodium chloride 10 mg, citric acid 5 mg, magnesium stearate 1 mg, orange flavoring 40 mg.

One tablet contains 1 g of sorbitol sweetener, which corresponds to approximately 17 kJ (4 kcal).

Description:

Round, biconcave tablets with the logo of the firm Zyma (two triangles located opposite each other with some displacement) on one side and the OR code on the back, white with a yellowish tinge, with an orange smell.

Pharmacotherapeutic group:antiseptic + local anesthetic
ATX: & nbsp
  • Other drugs
    • Pharmacodynamics:

    Benzoxonium chloride - quaternary ammonium salt (N-benzyl N-dodecyl N, N-di (2-hydroxyethyl)ammonium chloride), due to its cationic structure, possesses membrane-active activity and has a pronounced antibacterial effect against Gram-positive and, to a lesser extent, Gram-negative microorganisms. Benzoxonium also possesses antifungal and antiviral activity in relation to membrane viruses (incl.viruses of influenza, parainfluenza and herpes).

    Lidocaine is a local anesthetic, which in inflammatory processes reduces pain in the throat when swallowing.

    Pharmacokinetics:

    Benzoxonium chloride practically not absorbed. In humans, approximately 1% of the administered dose is found in the urine, the concentration of the substance in the blood is not detected. There was no accumulation of substance in the tissues of the body.

    Lidocaine It is absorbed when taken orally and through the oral mucosa. Metabolized by the "first" passage through the liver, with oral administration, its bioavailability is approximately 35%. Metabolites are excreted together with urine, less than 10% of the substance is excreted unchanged.

    Indications:

    Infections of the mouth and throat: pharyngitis, laryngitis, catarrhal angina, stomatitis, ulcerative gingivitis.

    As an auxiliary - chronic tonsillitis.

    Contraindications:

    Hypersensitivity to lidocaine or ammonia compounds.

    It is not recommended to use the drug for children under 4 years, in the first trimeter of pregnancy and during breastfeeding.

    Pregnancy and lactation:

    Effects of the drug on reproductive function and fetal development in the experiment was not found. Controlled studies involving pregnant women have not been conducted, and therefore Teraflu® LAR should not be used during pregnancy, especially in the first trimester.

    There are no clinical data on the penetration of the active ingredient into breast milk. Nevertheless, the drug is not recommended for use during breastfeeding.

    Dosing and Administration:

    Inside.

    Single dose - 1 tablet every 2-3 hours. With severe symptoms of the disease, 1 tablet every 1-2 hours. The tablet should dissolve slowly in the mouth.

    The daily dose should not exceed 10 tablets.

    Children: Teraflu® LAR can be used in children from the age of 4, 1 tablet every 2-3 hours. The daily dose should not exceed 6 tablets.

    Side effects:

    Sometimes, when Teraflu® LRA is used, local irritation is observed, which is temporary.

    Allergic reactions are rare.

    During the application of the drug for more than 2 weeks, a reversible brown color of the tongue or teeth may be observed.

    Overdose:

    Accidental administration of large doses of Teraflu® LAR, as well as other ammonia compounds, can lead to nausea or vomiting.

    When an overdose is recommended, drink milk or eat egg whites, whipped in water.

    The content of lidocaine in Teraflu® LAR is insignificant and can not cause serious symptoms of an overdose.
    Interaction:

    The effectiveness of benzoxonium chloride decreases with simultaneous intake of anionic-active agents, for example, toothpaste.

    Alcohol increases the absorption of benzoxonium chloride (avoid drinking alcohol during therapy).

    Effect on the ability to drive transp. cf. and fur:

    Does not affect.

    Form release / dosage:Lozenges.
    Packaging:

    8 tablets are packed in a blister of the combined material PVC / PE / PVDC / aluminum foil.

    One, two or three blisters are placed together with the instructions for use in a pack of cardboard.

    Storage conditions:

    Store in a dry place, at a temperature below 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-002042
    Date of registration:17.06.2011
    The owner of the registration certificate:Новартис Консьюмер Хелс САНовартис Консьюмер Хелс СА Switzerland
    Manufacturer: & nbsp
    Representation: & nbspNovartis Consumer Helms Ltd.Novartis Consumer Helms Ltd.
    Information update date: & nbsp18.03.2016
    Illustrated instructions
      Instructions
      Up